200 related articles for article (PubMed ID: 30816279)
1. CRISPR-mediated activation of endogenous BST-2/tetherin expression inhibits wild-type HIV-1 production.
Zhang Y; Ozono S; Yao W; Tobiume M; Yamaoka S; Kishigami S; Fujita H; Tokunaga K
Sci Rep; 2019 Feb; 9(1):3134. PubMed ID: 30816279
[TBL] [Abstract][Full Text] [Related]
2. Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex.
Saayman SM; Lazar DC; Scott TA; Hart JR; Takahashi M; Burnett JC; Planelles V; Morris KV; Weinberg MS
Mol Ther; 2016 Mar; 24(3):488-98. PubMed ID: 26581162
[TBL] [Abstract][Full Text] [Related]
3. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates.
Chen CY; Shingai M; Welbourn S; Martin MA; Borrego P; Taveira N; Strebel K
J Virol; 2016 Dec; 90(24):11062-11074. PubMed ID: 27681141
[TBL] [Abstract][Full Text] [Related]
5. A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from antagonizing the host restriction factor BST-2.
Mi Z; Ding J; Zhang Q; Zhao J; Ma L; Yu H; Liu Z; Shan G; Li X; Zhou J; Wei T; Zhang L; Guo F; Liang C; Cen S
Sci Rep; 2015 Dec; 5():18499. PubMed ID: 26669976
[TBL] [Abstract][Full Text] [Related]
6. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
7. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
[TBL] [Abstract][Full Text] [Related]
8. TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+ T cells across the virological synapse.
Blanchet FP; Stalder R; Czubala M; Lehmann M; Rio L; Mangeat B; Piguet V
Retrovirology; 2013 Jan; 10():6. PubMed ID: 23311681
[TBL] [Abstract][Full Text] [Related]
9. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
10. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.
Tokarev A; Skasko M; Fitzpatrick K; Guatelli J
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1197-210. PubMed ID: 19929170
[TBL] [Abstract][Full Text] [Related]
11. Tetherin/BST-2: Restriction Factor or Immunomodulator?
Li SX; Barrett BS; Guo K; Santiago ML
Curr HIV Res; 2016; 14(3):235-46. PubMed ID: 26957198
[TBL] [Abstract][Full Text] [Related]
12. High-Throughput NanoBiT-Based Screening for Inhibitors of HIV-1 Vpu and Host BST-2 Protein Interaction.
Li B; Dong X; Zhang W; Chen T; Yu B; Zhao W; Yang Y; Wang X; Hu Q; Wang X
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502213
[TBL] [Abstract][Full Text] [Related]
13. BST-2 restricts IAV release and is countered by the viral M2 protein.
Hu S; Yin L; Mei S; Li J; Xu F; Sun H; Liu X; Cen S; Liang C; Li A; Guo F
Biochem J; 2017 Feb; 474(5):715-730. PubMed ID: 28087685
[TBL] [Abstract][Full Text] [Related]
14. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Regulation of
Singh R; Ramsuran V; Naranbhai V; Yende-Zuma N; Garrett N; Mlisana K; Dong KL; Walker BD; Abdool Karim SS; Carrington M; Ndung'u T
Front Immunol; 2021; 12():669241. PubMed ID: 34025670
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition of HIV virus-like particles production by BST-2].
Du YL; Hu SQ; Pang XJ; Cen S; Jin Q; Guo F
Bing Du Xue Bao; 2011 Jul; 27(4):319-25. PubMed ID: 21874899
[TBL] [Abstract][Full Text] [Related]
17. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells.
Jolly C; Booth NJ; Neil SJ
J Virol; 2010 Dec; 84(23):12185-99. PubMed ID: 20861257
[TBL] [Abstract][Full Text] [Related]
18. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu.
Andrew AJ; Miyagi E; Kao S; Strebel K
Retrovirology; 2009 Sep; 6():80. PubMed ID: 19737401
[TBL] [Abstract][Full Text] [Related]
19. Human BST-2/tetherin inhibits Junin virus release from host cells and its inhibition is partially counteracted by viral nucleoprotein.
Zadeh VR; Urata S; Sakaguchi M; Yasuda J
J Gen Virol; 2020 Jun; 101(6):573-586. PubMed ID: 32375950
[TBL] [Abstract][Full Text] [Related]
20. High-throughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2.
Zhang Q; Liu Z; Mi Z; Li X; Jia P; Zhou J; Yin X; You X; Yu L; Guo F; Ma J; Liang C; Cen S
Antiviral Res; 2011 Sep; 91(3):321-9. PubMed ID: 21777622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
